SEATTLE GENETICS INC /WA

Form 4 June 13, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Baker Biotech Capital (GP), LLC

2. Issuer Name and Ticker or Trading

Symbol

SEATTLE GENETICS INC /WA [SGEN]

(Check all applicable)

(Last)

(First) (Middle) 3. Date of Earliest Transaction

4. If Amendment, Date Original

(Month/Day/Year)

_X__ 10% Owner _X__ Director __ Other (specify Officer (give title

5. Relationship of Reporting Person(s) to

667 MADISON AVE 17TH FLOOR (Street)

06/09/2006

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

Issuer

below)

NEW YORK, NY 10021

(City)	(State)	(Zip) Tab	ole I - Non-	Derivative S	Securi	ties Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securitie omr Dispose (Instr. 3, 4	d of (I	D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock (1)	06/09/2006		P	17,817	A	\$ 4.11	685,105	I	See footnote (3)
Common Stock (1) (2)	06/09/2006		P	460,379	A	\$ 4	1,145,484	I	See footnote (3)
Common Stock (1)	06/13/2006		P	6,110	A	\$ 3.9	1,151,594	I	See footnote (3)
Common Stock (1)	06/13/2006		P	13,066	A	\$ 4.0161	1,164,660	I	See footnote

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

(2) (3) Common See Stock (1) 06/13/2006 footnote (2) (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

9. Nu

Deriv

Secu

Bene

Own

Follo

Repo

Trans

(Insti

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2. 3. Transaction Date 3A. Deemed 8. Price of 4. 5. 6. Date Exercisable and 7. Title and Derivative Conversion (Month/Day/Year) Execution Date, if TransactionNumber **Expiration Date** Amount of Derivative Security or Exercise Code of (Month/Day/Year) Underlying Security Price of (Instr. 8) Derivative Securities (Instr. 3) (Month/Day/Year) (Instr. 5) Derivative Securities (Instr. 3 and 4) Security Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Amount Date Expiration Title Number Exercisable Date of Shares Code V (A) (D)

Reporting Owners

Reporting Owner Name / Address		Relationships					
reporting o wher runner, runners	Director	10% Owner	Officer	Other			
Baker Biotech Capital (GP), LLC 667 MADISON AVE 17TH FLOOR NEW YORK, NY 10021	X	X					
BAKER JULIAN 667 MADISON AVENUE NEW YORK, NY 10021	X						
BAKER FELIX 667 MADISON AVENUE NEW YORK, NY 10021	X						

Signatures

/s/ Julian C. Baker, as Managing Member of Baker Biotech Capital (GP), LLC

06/13/2006

**Signature of Reporting Person

Date

Reporting Owners 2

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

/s/ Julian C. Baker

**Signature of Reporting Person

Date

/s/ Felix J. Baker

06/13/2006

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- In addition to Baker Biotech Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Biotech Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons have filed on Schedule 13D as if they were a member of a group of such shareholders. (Continued in footnote 2.)
 - However, the Reporting Persons disclaim that they and any other person or persons, including those persons with whom the Reporting Persons have filed a Schedule 13D, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934,
- (2) as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein. Felix J. Baker is a director of the Issuer.
- Represents shares of common stock owned directly by Baker Biotech Fund I, L.P., the sole general partner of which is Baker Biotech (3) Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Felix J. Baker and Julian C. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3